Editorial Material
Hematology
Elias Jabbour, Hagop Kantarjian
Summary: Brivio et al demonstrate in their study that inotuzumab ozogamicin is safe and effective for pediatric relapsed-refractory ALL, with a recommended dose of 1.8 mg/m(2.1).
Article
Hematology
Jochim Reinert, Antonia Beitzen-Heineke, Klaus Wethmar, Matthias Stelljes, Walter Fiedler, Stefan Schwartz
Summary: This study presents flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. Additionally, comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities are provided.
ANNALS OF HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Chaoling Feng, Jinghui Dong, Tong Shen, Francesca Milletti, John M. Rossi, Remus Vezan, Behzad Kharabi Masouleh, Roch Houot
Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.
Article
Oncology
Warren Fingrut, Wendy Davis, Eric McGinnis, Karen Dallas, Khaled Ramadan, Hayley Merkeley, Heather Leitch, Yasser Abou Mourad, Ryan D. Cassaday, Camilla Ross, Chantal Leger
Summary: This case demonstrates that some B-ALL patients may respond to InO even with low CD22 expression, achieving survival benefits. This has important implications for clinicians managing B-ALL patients in selecting treatment options.
Article
Hematology
Erica Brivio, Christophe F. Chantrain, Tanja A. Gruber, Adriana Thano, Fanny Rialland, Audrey Contet, Sarah Elitzur, Luciano Dalla-Pozza, Krisztian Miklos Kallay, Chi-kong Li, Motohiro Kato, Inna Markova, Kjeld Schmiegelow, Nicole Bodmer, Erin H. Breese, Raoull Hoogendijk, Rob Pieters, Christian Michel Zwaan
Summary: This study collected data on infants and young children under 3 years old with ALL who were treated with InO, showing a 47% complete remission rate and a 6-month overall survival rate of 47%. However, two patients experienced veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL patients is warranted.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Edoardo Pennesi, Naomi Michels, Erica Brivio, Vincent H. J. van der Velden, Yilin Jiang, Adriana Thano, Anneke J. C. Ammerlaan, Judith M. Boer, H. Berna Beverloo, Barbara Sleight, Ying Chen, Britta Vormoor-Buerger, Susana Rives, Bella Bielorai, Claudia Roessig, Arnaud Petit, Carmelo Rizzari, Gernot Engstler, Jan Stary, Francisco J. Bautista Sirvent, Christiane Chen-Santel, Benedicte Bruno, Yves Bertrand, Fanny Rialland, Genevieve Plat, Dirk Reinhardt, Luciana Vinti, Arend Von Stackelberg, Franco Locatelli, Christian M. Zwaan
Summary: Inotuzumab Ozogamicin has shown promising efficacy in relapsed or refractory B cell acute lymphoblastic leukemia, with a high overall response rate and a significant reduction in minimal residual disease. However, the occurrence of sinusoidal obstructive syndrome, especially after HSCT treatment, is a major concern.
Article
Oncology
Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani
Summary: Inotuzumab ozogamicin demonstrated superior response rates, minimal/measurable residual disease negativity, longer duration of remission, and better overall survival compared to standard of care in patients with CD22 positivity >= 90%. Patients with CD22 positivity <90% showed higher response rates with inotuzumab ozogamicin therapy, but similar duration of remission and overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Maria C. Pirosa, Lu Zhang, Felicitas Hitz, Urban Novak, Dagmar Hess, Tatiana Terrot, Mariarosa Pascale, Luca Mazzucchelli, Francesco Bertoni, Franco Cavalli, Emanuele Zucca, Anastasios Stathis
Summary: This phase I trial assessed the safety, tolerability, and preliminary activity of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed/refractory CD22 positive B-cell non-Hodgkin lymphomas. The recommended phase II dose was inotuzumab ozogamicin 0.8 mg/m(2) on day 1 in combination with temsirolimus 10 mg on days 8, 15, and 22 every 28 days. Antitumor activity was observed in heavily pretreated patients, but the drug combination was not feasible within a therapeutically useful range of doses due to toxicities.
LEUKEMIA & LYMPHOMA
(2022)
Article
Chemistry, Medicinal
Lei He, Liangliang Wang, Zhisong Wang, Tiantian Li, Hui Chen, Yaning Zhang, Zeping Hu, Dimiter S. Dimitrov, Juanjuan Du, Xuebin Liao
Summary: The ADC HE-S2, constructed by conjugating anti-PD-L1 THIOMAB with bifunctional immunomodulator D18, enhances antitumor immune response through multiple pathways, making it more sensitive to PD-1/PD-L1 blockade and effectively suppressing tumor growth.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Nicola Stefano Fracchiolla, Mariarita Sciume, Cristina Papayannidis, Antonella Vitale, Sabina Chiaretti, Mario Annunziata, Fabio Giglio, Prassede Salutari, Fabio Forghieri, Davide Lazzarotto, Monia Lunghi, Annalisa Imovilli, Barbara Scappini, Massimiliano Bonifacio, Michelina Dargenio, Carmela Gurrieri, Elisabetta Todisco, Marzia Defina, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Cerrano, Lidia Santoro, Elena Tagliaferri, Enrico Barozzi, Pasquale De Roberto, Marta Canzi, Elisa Buzzatti, Chiara Sartor, Francesco Passamonti, Robin Foa, Antonio Curti, Thomas Wirth
Summary: This retrospective study evaluated the efficacy and safety of blinatumomab and inotuzumab ozogamicin in the treatment of relapsed B-lymphoblastic leukemia. The study demonstrated the feasibility and effectiveness of sequential immunotherapy using these two drugs in terms of minimal residual disease, overall survival, and disease-free survival.
Article
Rheumatology
Jing Li, Mengtao Li, Di Wu, Jiaxin Zhou, Shui-on Leung, Fengchun Zhang
Summary: This study evaluated the efficacy and safety of SM03 in Chinese patients with RA. The results showed that SM03 had good efficacy and safety at cumulative doses of 2400mg and 3600mg.
Article
Genetics & Heredity
Sumiko Maristany, Adam S. DuVall, Wendy Stock, Amanda J. Adeleye
Summary: Recent advances in targeted therapy with monoclonal antibodies have greatly improved cancer outcomes, but there is still a need for further research on their effects on fertility. This article presents a case of rapid onset primary ovarian insufficiency in a 23-year-old patient following treatment with a monoclonal antibody drug-conjugate, highlighting the potential impact of such therapies on ovarian function.
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
(2022)
Review
Oncology
Elias Jabbour, Shilpa Paul, Hagop Kantarjian
Summary: Advances in cancer biology have led to the development of antibody-drug conjugates (ADCs), which combine the selectivity of therapeutic antibodies with the cytotoxicity of small molecules for targeted therapies. The success of ADCs depends on the specific properties of their components, impacting stability, pharmacokinetics, and antitumor activity. ADCs like gemtuzumab ozogamicin and inotuzumab ozogamicin have provided valuable insights for optimizing these agents for clinical use.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Joseph Chen, May Haughey, Erik Vandendries, Daniel J. DeAngelo, Hagop M. Kantarjian, Ana Ruiz-Garcia
Summary: InO exposure is significantly correlated with achieving complete remission and minimal residual disease elimination in ALL patients, with significantly higher odds of achieving these endpoints in patients treated with InO compared to those receiving chemotherapy.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2021)
Review
Immunology
Jeremy D. D. Rubinstein, Maureen M. M. O'Brien
Summary: InO is an antibody drug conjugate used to treat relapsed and refractory B-cell precursor acute lymphoblastic leukemia. It has shown significant activity in both adult and pediatric trials. However, there are notable toxicities including sinusoidal obstruction syndrome and myelosuppression. In the relapsed/refractory setting, the subsequent curative therapy modality must be considered to mitigate these risks.
FRONTIERS IN IMMUNOLOGY
(2023)